Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and Kaposi sarcoma [0.03%]
卡波西肉瘤相关疱疹病毒/人类第八型疱疹病毒和卡波氏肉瘤
J N Martin
J N Martin
Kaposi sarcoma-associated herpesvirus (KSHV) was discovered in 1994 and is now known to be a necessary but not sufficient causative agent of Kaposi sarcoma. While KSHV is likely also the causative agent of primary effusion lymphoma and mult...
Y Chu,H Liu
Y Chu
The current approach for dealing with the global pandemic of AIDS focuses on pharmaceuticals. The classic treatment of AIDS is highly active antiretroviral therapy, but most people living with HIV/AIDS-especially those in developing countri...
V Yengopal,A Bhayat,M Coogan
V Yengopal
This article is a review of the literature between 2003 (since the last workshop) and April 2009 (Beijing workshop). It focuses on the prevalence of oral lesions associated with HIV infection, oral lesions as predictors of HIV infection, or...
Effect of traditional Chinese medicinal herbs on Candida spp. from patients with HIV/AIDS [0.03%]
中药对HIV/AIDS患者体内白色念珠菌的体外抑制作用研究
X Liu,Y Han,K Peng et al.
X Liu et al.
As an opportunistic infection, candidiasis is common among individuals infected with HIV. About 90% of patients develop oral and/or oropharyngeal candidiasis in various stages of AIDS. Triazole antifungal agents, such as fluconazole and itr...
J R Naglik,D Moyes
J R Naglik
With the advent of treatments and diseases such as AIDS resulting in increasing numbers of patients with suppressed immune systems, fungal diseases are an escalating problem. Candida albicans is the most common of these fungal pathogens, ca...
Candida-host interactions in HIV disease: implications for oropharyngeal candidiasis [0.03%]
念珠菌与宿主在艾滋病病程中的相互作用及假丝酵母菌型口腔炎的含义
P L Fidel Jr
P L Fidel Jr
Oropharyngeal candidiasis (OPC), caused primarily by Candida albicans, is the most common oral infection in HIV(+) persons. Although Th1-type CD4(+) T cells are the predominant host defense mechanism against OPC, CD8(+) T cells and epitheli...
M C Herzberg,A Vacharaksa,K H Gebhard et al.
M C Herzberg et al.
The AIDS pandemic continues. Little is understood about how HIV gains access to permissive cells across mucosal surfaces, yet such knowledge is crucial to the development of successful topical anti-HIV-1 agents and mucosal vaccines. HIV-1 r...
D Malamud,W R Abrams,C A Barber et al.
D Malamud et al.
In this review, the authors survey the large number of antibacterial and antiviral proteins present in human saliva. Of interest, most of these antibacterial proteins display antiviral activity, typically against specific viral pathogens. T...
C H Shiboski,J Y Webster-Cyriaque,M Ghannoum et al.
C H Shiboski et al.
The Oral HIV/AIDS Research Alliance is part of the AIDS Clinical Trials Group, the largest HIV clinical trial organization in the world, and it is funded by the National Institute of Dental and Craniofacial Research, in collaboration with t...
B S Peters,K Conway
B S Peters
Initial therapies for HIV infection comprised nucleoside analogues, but as single or dual agents, they failed to prevent disease progression. When a new class of drug was introduced, the protease inhibitors, an effective triple therapy beca...